Experimental Study On Biodistribution And Anticancer Activity Of ～(131)I-Herceptin In Breast Cancer Xenograft

Background and objectives:The HER2, a kind of glycoprotein across the membrane with the molecule weight of 185 kDa,is a member of the epidermal growth factor receptor family and plays important roles in the course of signal conduction and phosphorylation of cistine in the cell.Studies have proved that HER2 is overexpressed in 20 to 30 percent of patients with metastatic breast cancer and the expression of HER2 on these cancer cells is 10 to 100-fold as that on normal breast tissue around the cancer.These patients are always aggressive and with poor prognosis,resistant to chemical therapy and endocrine therapy such as tamoxifen.So there is no effective method for these patients at present.Hence targeting HER2 and obstructing the proliferation of tumor cells by receptor-mediated steadily have become the study hotspot for metastatic breast cancer.Herceptin is a kind of anti-HER2 humanized monoclonal antibody.It plays importmant role in targeted therapy for HER2 overexpressing metastatic breast cancer as a single agent or combined with chemical drugs such as adriamycin,taxines and cisplatin.But the clinic effective rate was limited as low as 12 to 24 percent when Herceptin was used as a single agent.And when combined with chemotherapy,it...